Jarnagin W R, Fong Y, DeMatteo R P, Gonen M, Burke E C, Bodniewicz BS J, Youssef BA M, Klimstra D, Blumgart L H
Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9. doi: 10.1097/00000658-200110000-00010.
To analyze resectability and survival in patients with hilar cholangiocarcinoma according to a proposed preoperative staging scheme that fully integrates local, tumor-related factors.
In patients with hilar cholangiocarcinoma, long-term survival depends critically on complete tumor resection. The current staging systems ignore factors related to local tumor extent, preclude accurate preoperative disease assessment, and correlate poorly with resectability and survival.
Demographics, results of imaging studies, surgical findings, pathology, and survival were analyzed prospectively in consecutive patients. Using data from imaging studies, all patients were placed into one of three stages based on the extent of ductal involvement by tumor, the presence or absence of portal vein compromise, and the presence or absence of hepatic lobar atrophy.
From March 1991 through December 2000, 225 patients were evaluated, 77% of whom were seen and treated within the last 6 years. Sixty-five patients had unresectable disease; 160 patients underwent exploration with curative intent. Eighty patients underwent resection: 62 (78%) had a concomitant hepatic resection and 62 (78%) had an R0 resection (negative histologic margins). Negative histologic margins, concomitant partial hepatectomy, and well-differentiated tumor histology were associated with improved outcome after all resections. However, in patients who underwent an R0 resection, concomitant partial hepatectomy was the only independent predictor of long-term survival. Of the 9 actual 5-year survivors (of 30 at risk), all had a concomitant hepatic resection and none had tumor-involved margins; 3 of these 9 patients remained free of disease at a median follow-up of 88 months. The rates of complications and death after resection were 64% and 10%, respectively. In the 219 patients whose disease could be staged, the proposed system predicted resectability and the likelihood of an R0 resection and correlated with metastatic disease and survival.
By taking full account of local tumor extent, the proposed staging system for hilar cholangiocarcinoma accurately predicts resectability, the likelihood of metastatic disease, and survival. Complete resection remains the only therapy that offers the possibility of long-term survival, and hepatic resection is a critical component of the surgical approach.
根据一种全面整合局部、肿瘤相关因素的术前分期方案,分析肝门部胆管癌患者的可切除性及生存率。
在肝门部胆管癌患者中,长期生存严重依赖于肿瘤的完整切除。当前的分期系统忽略了与局部肿瘤范围相关的因素,无法进行准确的术前疾病评估,且与可切除性及生存率的相关性较差。
对连续患者的人口统计学资料、影像学检查结果、手术发现、病理及生存情况进行前瞻性分析。利用影像学检查数据,根据肿瘤侵犯胆管的范围、门静脉是否受侵犯以及肝叶是否萎缩,将所有患者分为三个阶段之一。
1991年3月至2000年12月,共评估了225例患者,其中77%在过去6年内就诊并接受治疗。65例患者患有不可切除的疾病;160例患者接受了根治性手术探查。80例患者接受了切除术:62例(78%)同时进行了肝切除术,62例(78%)实现了R0切除(组织学切缘阴性)。组织学切缘阴性、同时进行部分肝切除术以及肿瘤组织学高分化与所有切除术后的良好预后相关。然而,在接受R0切除的患者中,同时进行部分肝切除术是长期生存的唯一独立预测因素。在9例实际的5年生存者(30例有风险者中)中,均同时进行了肝切除术,且均无肿瘤累及切缘;这9例患者中有3例在中位随访88个月时仍无疾病复发。切除术后的并发症发生率和死亡率分别为64%和10%。在219例可分期的患者中,所提出的系统预测了可切除性及R0切除的可能性,并与转移性疾病及生存率相关。
通过充分考虑局部肿瘤范围,所提出的肝门部胆管癌分期系统准确预测了可切除性、转移性疾病的可能性及生存率。完整切除仍然是唯一有可能实现长期生存的治疗方法,肝切除术是手术方法的关键组成部分。